You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Ovarian cancer using novel nanoparticle formulations

    SBC: KIROMIC BIOPHARMA INC            Topic: 102

    DESCRIPTION provided by applicant Ovarian cancer is the fifth most leading cause of cancer related deaths in women in the US It has been observed that the cancer relapses within relatively short periods of time even after the surgery and chemotherapy Therefore immunotherapeutic strategies may serve as an alternative to control the recurrence or progression of ovarian cancer Oral vaccines ar ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Optimized lactoferrin for treatment of intracerebral hemorrhage

    SBC: Pharmareview Corporation            Topic: NINDS

    DESCRIPTION provided by applicant Intracerebral hemorrhage ICH is a major public health problem with highest mortality rate of all stroke subtypes and long term disability Since there are no available FDA approved therapies for ICH it is of enormous importance to establish effective treatment for this medical condition Following ICH the deposited blood is damaging initially via compression ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. High Spatial Resolution Ultrafast Sum-Frequency Generation Microscope

    SBC: PHYSICS, MATERIALS, AND APPLIED MATHEMATICS RESEARCH L.L.C.            Topic: 07a

    Vibrationally resonant sum-frequency generation (SFG) spectroscopy is a second order nonlinear optical technique that features high chemical selectivity and a set of selection rules that makes it an ideal complement to coherent Raman scattering (CRS) as an imaging tool. Attempts have been made to construct high-resolution, high speed SFG microscopes, but to date both the resolving power and image ...

    STTR Phase I 2014 Department of Energy
  5. Uniform, High Intensity X-ray Source for Blood Irradiation

    SBC: National Nanomaterials, Inc            Topic: 22a

    There is an ongoing effort to replace high activity radioactive sources that could pose a risk for use as terrorist weapons with non-radioisotope based technologies. Currently radioactive sources serve a number of critical needs including the treatment and diagnosis of disease, inspection and certification of critical mechanical structures, the sterilization of food and medical products, ...

    STTR Phase I 2014 Department of Energy
  6. Next Generation Semiconductor-Based Radiation Detectors Using Cadmium Magnesium Telluride

    SBC: BRIMROSE TECHNOLOGY CORP            Topic: 23c

    At present, CdZnTe is considered the material of choice for efficient, room temperature gamma-radiation detection systems used for the detection and identification of radionuclides. Despite the advances in CdZnTe materials technology during the last decade, the major impediments in the progress of - ray detection technology are the low yield of device quality materials and detectors, and the limit ...

    STTR Phase I 2014 Department of Energy
  7. Development of VPL Vaccine for RSV

    SBC: SIGMOVIR BIOSYSTEMS, INC.            Topic: NIAID

    Project Summary Human respiratory syncytial virus (RSV) is recognized as the single most important viral cause of acute respiratory disease in infants and young children worldwide. Elderly populations and immunocompromised individuals are also at significant risk for serious RSV disease. Despite this very substantial disease burden imposed by RSV worldwide, there are no vaccines available. Severa ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Surface-covering gels for broad-spectrum antimicrobial protection following open

    SBC: SONORAN BIOSCIENCES INC            Topic: NIAMS

    DESCRIPTION (provided by applicant): About 3-4% of all fractures are estimated to be open fractures, where the fracture is exposed through defects in the skin and soft tissues. This equates to about 250,000 open fractures in the United States annually. Open fractures present a high risk of infection. Infection results in considerable financial burden to both the patient an healthcare system, requ ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Ex vivo purging strategy for treatment of multiple myeloma

    SBC: DNATRIX INC            Topic: NCI

    DESCRIPTION (provided by applicant): The ultimate goal of this application is to develop a novel ex vivo purging method using myxoma virus (MYXV), a rabbit-specific poxvirus, to improve the clinical outcomes in treatment of multiple myeloma (MM). MM is aclonal plasma cell malignancy that has to date resisted essentially all therapeutic strategies. Currently, the standard of care for patients wit ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics

    SBC: PPI PHARMACEUTICALS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): As cancer is one of the leading causes of death in the United States with some sub-types remaining essentially untreatable, expansion of available drug targets will provide significant new options for the development ofmore effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development. Th ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government